-
Je něco špatně v tomto záznamu ?
Cytochrome b(5) shifts oxidation of the anticancer drug ellipticine by cytochromes P450 1A1 and 1A2 from its detoxication to activation, thereby modulating its pharmacological efficacy
V. Kotrbová, B. Mrázová, M. Moserová, V. Martínek, P. Hodek, J. Hudeček, E. Frei, M. Stiborová,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- adukty DNA metabolismus MeSH
- antitumorózní látky fytogenní chemie metabolismus farmakologie MeSH
- cytochrom P-450 CYP1A1 metabolismus MeSH
- cytochromy metabolismus MeSH
- elipticiny chemie metabolismus farmakologie MeSH
- hemoproteiny metabolismus MeSH
- injekce intraperitoneální MeSH
- jaterní mikrozomy účinky léků enzymologie metabolismus MeSH
- krysa rodu rattus MeSH
- metabolická inaktivace MeSH
- oxidace-redukce MeSH
- potkani Wistar MeSH
- transportní proteiny metabolismus MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Ellipticine is a pro-drug, whose activation is dependent on its oxidation by cytochromes P450 (CYP) and peroxidases. Cytochrome b(5) alters the ratio of ellipticine metabolites formed by isolated reconstituted CYP1A1 and 1A2, favoring formation of 12-hydroxy- and 13-hydroxyellipticine metabolites implicated in ellipticine-DNA adduct formation, at the expense of 9-hydroxy- and 7-hydroxyellipticine that are detoxication products. Cytochrome b(5) enhances the production of 12-hydroxy and 13-hydroxyellipticine. The change in metabolite ratio results in an increased formation of covalent ellipticine-DNA adducts, one of the DNA-damaging mechanisms of ellipticine antitumor action. This finding explains previous apparent discrepancies found with isolated enzymes and in vivo, where CYP1A enzymatic activation correlated with ellipticine-DNA-adduct levels while isolated CYP1A1 or 1A2 in reconstituted systems were much less effective than CYP3A4. The effect of cytochrome b(5) might be even more pronounced in vivo, since, as we show here, ellipticine increases levels of cytochrome b(5) in rat liver. Our results demonstrate that both the native 3D structure of cytochrome b(5) and the presence of the heme as an electron transfer agent in this protein enable a shift in ellipticine metabolites formed by CYP1A1/2.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12028239
- 003
- CZ-PrNML
- 005
- 20121206114304.0
- 007
- ta
- 008
- 120817e20110613enk f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.bcp.2011.06.003 $2 doi
- 035 __
- $a (PubMed)21683692
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Kotrbová, Věra $u Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, 128 40 Prague 2, Czech Republic.
- 245 10
- $a Cytochrome b(5) shifts oxidation of the anticancer drug ellipticine by cytochromes P450 1A1 and 1A2 from its detoxication to activation, thereby modulating its pharmacological efficacy / $c V. Kotrbová, B. Mrázová, M. Moserová, V. Martínek, P. Hodek, J. Hudeček, E. Frei, M. Stiborová,
- 520 9_
- $a Ellipticine is a pro-drug, whose activation is dependent on its oxidation by cytochromes P450 (CYP) and peroxidases. Cytochrome b(5) alters the ratio of ellipticine metabolites formed by isolated reconstituted CYP1A1 and 1A2, favoring formation of 12-hydroxy- and 13-hydroxyellipticine metabolites implicated in ellipticine-DNA adduct formation, at the expense of 9-hydroxy- and 7-hydroxyellipticine that are detoxication products. Cytochrome b(5) enhances the production of 12-hydroxy and 13-hydroxyellipticine. The change in metabolite ratio results in an increased formation of covalent ellipticine-DNA adducts, one of the DNA-damaging mechanisms of ellipticine antitumor action. This finding explains previous apparent discrepancies found with isolated enzymes and in vivo, where CYP1A enzymatic activation correlated with ellipticine-DNA-adduct levels while isolated CYP1A1 or 1A2 in reconstituted systems were much less effective than CYP3A4. The effect of cytochrome b(5) might be even more pronounced in vivo, since, as we show here, ellipticine increases levels of cytochrome b(5) in rat liver. Our results demonstrate that both the native 3D structure of cytochrome b(5) and the presence of the heme as an electron transfer agent in this protein enable a shift in ellipticine metabolites formed by CYP1A1/2.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antitumorózní látky fytogenní $x chemie $x metabolismus $x farmakologie $7 D000972
- 650 _2
- $a transportní proteiny $x metabolismus $7 D002352
- 650 _2
- $a cytochrom P-450 CYP1A1 $x metabolismus $7 D019363
- 650 _2
- $a cytochromy $x metabolismus $7 D003580
- 650 _2
- $a adukty DNA $x metabolismus $7 D018736
- 650 _2
- $a elipticiny $x chemie $x metabolismus $x farmakologie $7 D004611
- 650 _2
- $a hemoproteiny $x metabolismus $7 D006420
- 650 _2
- $a injekce intraperitoneální $7 D007274
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a metabolická inaktivace $7 D008658
- 650 _2
- $a jaterní mikrozomy $x účinky léků $x enzymologie $x metabolismus $7 D008862
- 650 _2
- $a oxidace-redukce $7 D010084
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Mrázová, Barbora
- 700 1_
- $a Moserová, Michaela
- 700 1_
- $a Martínek, Václav
- 700 1_
- $a Hodek, Petr
- 700 1_
- $a Hudeček, Jiří
- 700 1_
- $a Frei, Eva
- 700 1_
- $a Stiborová, Marie
- 773 0_
- $w MED00000704 $t Biochemical pharmacology $x 1873-2968 $g Roč. 82, č. 6 (20110613), s. 669-80
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21683692 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20121206114337 $b ABA008
- 999 __
- $a ok $b bmc $g 950281 $s 785585
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2011 $b 82 $c 6 $d 669-80 $e 20110613 $i 1873-2968 $m Biochemical pharmacology $n Biochem Pharmacol $x MED00000704
- LZP __
- $a Pubmed-20120817/11/04